Intended Audience
This complimentary CME educational activity is designed for all healthcare providers (HCPs) involved in developing, delivering, consulting, and monitoring care for patients with moderate, moderately severe, and severe AD who are cared for both in the outpatient, assisted living, and skilled nursing facility.
This constituency of HCPs shall include the following audience:
Registration
Participation in this iQ&A interactive Medical Intelligence Zone for Alzheimer’s Disese is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.
Grantor Support
Supported by an educational grant from Eisai, Inc.
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Massachusetts Medical School Office of Continuing Medical Education (UMMS-OCME) and CMEducation Resources, LLC. The UMMS-OCME is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Massachusetts Medical School designates this enduring material for a maximum of 4.0 AMA PRA Category 1 Credits(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Policy on Faculty & Provider Disclosure
It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.
Policy on Faculty & Provider Disclosure
It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.
Program Faculty and Disclosure
David H. Cribbs, Ph.D.
Professor & Associate Director
Institute for Memory Impairments and Neurological Disorders
Department of Neurology
University of California, Irvine
Irvine, CA
Research Support: Boehringer-Ingelheim
Jeffrey Cummings, MD
Professor of Neurotherapeutics and Drug Development
Cleveland Clinic Lerner College of Medicine
Director, Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, NV
Consultant: Abbott, Acadia, Accera, Adamas, Astellas, Avanir, Bayer, Bristol-Myers Squibb, CoMentis, Eisai, Elan, EnVivo, Forest, GlaxoSmithKline, Janssen, Lilly, Lundbeck, Medivation, Medtronics, Merck, Merz, Myriad, Neuren, Neurokos, Novartis, Noven, Orion, Pfizer, Prana, reMYND, Schering-Plough, Signum, Sonexa, Takeda, Toyama, Wyeth
Speakers' Bureau: Eisai, Forest, Janssen, Lundbeck, Merz, Novartis, Pfizer;
Other: Owns the copyright of the Neuropsychiatric Inventory
Martin Farlow, MD
Professor of Neurology
Vice-Chairman of Research
Department of Neurology
Indiana University School of Medicine
Indianapolis, IN
Consultant: Accera, Inc.; Adamas Pharmaceuticals, Inc.; Adlyfe Inc.; Astellas Pharma US, Inc.; AstraZeneca Pharmaceuticals LP; CoMentis, Inc.; Eisai Inc.; Eli Lilly and Company; GlaxoSmithKline Inc.; Medivation, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Noven Pharmaceuticals, Inc.; Octapharma AG; QR Pharma; sanofi-aventis; Schering-Plough Corporation; and Toyama Chemical Co., Ltd. Grant/Research Support: Bristol-Myers Squibb Company; Elan Corporation, plc; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Octapharma AG; Pfizer Inc; and Sonexa Therapeutics, Inc.
Speakers Bureau: Eisai Inc.; Forest Pharmaceuticals, Inc.; Pfizer Inc; and Novartis Pharmaceuticals Corporation.
Honoraria: Accera, Inc.; Adamas Pharmaceuticals, Inc.; Adlyfe Inc.; Astellas Pharma US, Inc.; AstraZeneca Pharmaceuticals LP; CoMentis, Inc.; Eisai Inc.; Eli Lilly and Company; Forest Pharmaceuticals, Inc.; GlaxoSmithKline Inc.; Medivation, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Noven Pharmaceuticals, Inc.; Octapharma AG; Pfizer Inc; QR Pharma; sanofi-aventis; Schering-Plough Corporation; and Toyama Chemical Co., Ltd
Steven H. Ferris, PhD
Friedman Professor and Director
Alzheimer's Disease Center
Center of Excellence on Brain Aging
New York University Langone School of Medicine
New York, NY
Research Support: Alzheimer’s Disease Cooperative Study (NIH), Baxter, Bristol Myers- Squibb, Eli Lilly, Janssen Alzheimer Immunotherapy, Pfizer
Consultant: Accera, Bayer Healthcare, Bellus Health, CogniFit, Constellation Wines, Elan, Eli Lilly, Janssen Alzheimer Immunotherapy, Lundbeck, MedAvante, Merz Pharma, Neuroniz, Novartis, Otsuka, Pfizer, Toyama, United Biosource
Shareholder: Accera, Brain Savers, Intellect Neurosciences, MedAvante, Symphony Icon, Neuronix
Adam S. Fleisher, MD, MAS
Associate Director of Brain Imaging
Banner Alzheimer's Institute
Medical Director, Alzheimer's Disease Cooperative Study
Associate Professor, Department of Neurosciences
University of California, San Diego
Nothing to disclose
James E. Galvin, MD, MPH
Professor of Neurology and Psychiatry
Director of Clinical Operations, Center of Excellence on Brain Aging
Director, Pearl Barlow Center for Memory Evaluation and Treatment
New York University Langone School of Medicine
New York, NY
Clinical Trial Investigator: Novartis, Eli Lilly, Elan, Wyeth, and Bristol-Meyer-Squibb
Consultant: Novartis, Forest, Pfizer, Eisai and Medivation
Irving Gomolin MDCM, FACP, FRCPC
Chief, Division of Geriatric Medicine
Chief, Division of Clinical Pharmacology
Winthrop University Hospital
Mineola, NY
Nothing to disclose
Robert C. Green, MD, MPH
Fellow in Genetics/Professor of Neurology, Genetics, and Epidemiology
Division of Genetics, Department of Medicine
Brigham and Women’s Hospital
Harvard Medical School
Boston, MA
Nothing to disclose
Michael D. Greicius, MD, MPH
Medical Director, Stanford Memory Clinic
Stanford Hospitals & Clinics
Assistant Professor of Neurology
Stanford University School of Medicine
Stanford, CA
Patient Safety Monitoring Panel: Forest
John Olichney, MD
Associate Professor of Neurology
Center for Mind and Brain
UC Davis School of Medicine
Sacramento, CA
Nothing to disclose
Lon Schneider, MD, MS
Professor of Psychiatry, Neurology, and Gerontology
Keck School of Medicine
University of Southern California
Director, California Alzheimer's Disease Center
Do-director, Clinical Core
University of Southern California Alzheimer's Disease Research Center
Los Angeles, CA
Grant funding, contracts, and/or consulting: Lilly, Myriad, Lundbeck, Elan, Johnson and Johnson, Pfizer, Transition.
Thomas Wisniewski MD
Professor of Neurology, Pathology and Psychiatry
New York University School of Medicine
Dept. of Neurology, Psychiatry and Pathology
New York, NY
Nothing to disclose
Program Managers and Web Editor Disclosure Program Manager Gideon Bosker, MD has nothing to disclose.
Program Reviewer Denise Leary has nothing to disclose.
Educational Objectives
Upon completion of this activity, participants will be able to:
Hardware and Software Requirements:
To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate..
Privacy Policy
When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:
Disclaimer
Copyright © 2011 by Pharmatecture, LLC and CMEducation Resources, LLC All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.
Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.
This complimentary CME educational activity is designed for all healthcare providers (HCPs) involved in developing, delivering, consulting, and monitoring care for patients with moderate, moderately severe, and severe AD who are cared for both in the outpatient, assisted living, and skilled nursing facility.
This constituency of HCPs shall include the following audience:
- Primary care physicians
- Geriatric NPs
- PAs
- Neurologists
- Geriatricians
- Geropsychiatrists
- Geriatric nurse practitioners
- Clinical and consulting pharmacists
- Clinical nurses
- Case managers
- Other clinical providers for AD
Registration
Participation in this iQ&A interactive Medical Intelligence Zone for Alzheimer’s Disese is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.
Grantor Support
Supported by an educational grant from Eisai, Inc.
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Massachusetts Medical School Office of Continuing Medical Education (UMMS-OCME) and CMEducation Resources, LLC. The UMMS-OCME is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Massachusetts Medical School designates this enduring material for a maximum of 4.0 AMA PRA Category 1 Credits(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Policy on Faculty & Provider Disclosure
It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.
Policy on Faculty & Provider Disclosure
It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.
Program Faculty and Disclosure
David H. Cribbs, Ph.D.
Professor & Associate Director
Institute for Memory Impairments and Neurological Disorders
Department of Neurology
University of California, Irvine
Irvine, CA
Research Support: Boehringer-Ingelheim
Jeffrey Cummings, MD
Professor of Neurotherapeutics and Drug Development
Cleveland Clinic Lerner College of Medicine
Director, Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, NV
Consultant: Abbott, Acadia, Accera, Adamas, Astellas, Avanir, Bayer, Bristol-Myers Squibb, CoMentis, Eisai, Elan, EnVivo, Forest, GlaxoSmithKline, Janssen, Lilly, Lundbeck, Medivation, Medtronics, Merck, Merz, Myriad, Neuren, Neurokos, Novartis, Noven, Orion, Pfizer, Prana, reMYND, Schering-Plough, Signum, Sonexa, Takeda, Toyama, Wyeth
Speakers' Bureau: Eisai, Forest, Janssen, Lundbeck, Merz, Novartis, Pfizer;
Other: Owns the copyright of the Neuropsychiatric Inventory
Martin Farlow, MD
Professor of Neurology
Vice-Chairman of Research
Department of Neurology
Indiana University School of Medicine
Indianapolis, IN
Consultant: Accera, Inc.; Adamas Pharmaceuticals, Inc.; Adlyfe Inc.; Astellas Pharma US, Inc.; AstraZeneca Pharmaceuticals LP; CoMentis, Inc.; Eisai Inc.; Eli Lilly and Company; GlaxoSmithKline Inc.; Medivation, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Noven Pharmaceuticals, Inc.; Octapharma AG; QR Pharma; sanofi-aventis; Schering-Plough Corporation; and Toyama Chemical Co., Ltd. Grant/Research Support: Bristol-Myers Squibb Company; Elan Corporation, plc; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Octapharma AG; Pfizer Inc; and Sonexa Therapeutics, Inc.
Speakers Bureau: Eisai Inc.; Forest Pharmaceuticals, Inc.; Pfizer Inc; and Novartis Pharmaceuticals Corporation.
Honoraria: Accera, Inc.; Adamas Pharmaceuticals, Inc.; Adlyfe Inc.; Astellas Pharma US, Inc.; AstraZeneca Pharmaceuticals LP; CoMentis, Inc.; Eisai Inc.; Eli Lilly and Company; Forest Pharmaceuticals, Inc.; GlaxoSmithKline Inc.; Medivation, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Noven Pharmaceuticals, Inc.; Octapharma AG; Pfizer Inc; QR Pharma; sanofi-aventis; Schering-Plough Corporation; and Toyama Chemical Co., Ltd
Steven H. Ferris, PhD
Friedman Professor and Director
Alzheimer's Disease Center
Center of Excellence on Brain Aging
New York University Langone School of Medicine
New York, NY
Research Support: Alzheimer’s Disease Cooperative Study (NIH), Baxter, Bristol Myers- Squibb, Eli Lilly, Janssen Alzheimer Immunotherapy, Pfizer
Consultant: Accera, Bayer Healthcare, Bellus Health, CogniFit, Constellation Wines, Elan, Eli Lilly, Janssen Alzheimer Immunotherapy, Lundbeck, MedAvante, Merz Pharma, Neuroniz, Novartis, Otsuka, Pfizer, Toyama, United Biosource
Shareholder: Accera, Brain Savers, Intellect Neurosciences, MedAvante, Symphony Icon, Neuronix
Adam S. Fleisher, MD, MAS
Associate Director of Brain Imaging
Banner Alzheimer's Institute
Medical Director, Alzheimer's Disease Cooperative Study
Associate Professor, Department of Neurosciences
University of California, San Diego
Nothing to disclose
James E. Galvin, MD, MPH
Professor of Neurology and Psychiatry
Director of Clinical Operations, Center of Excellence on Brain Aging
Director, Pearl Barlow Center for Memory Evaluation and Treatment
New York University Langone School of Medicine
New York, NY
Clinical Trial Investigator: Novartis, Eli Lilly, Elan, Wyeth, and Bristol-Meyer-Squibb
Consultant: Novartis, Forest, Pfizer, Eisai and Medivation
Irving Gomolin MDCM, FACP, FRCPC
Chief, Division of Geriatric Medicine
Chief, Division of Clinical Pharmacology
Winthrop University Hospital
Mineola, NY
Nothing to disclose
Robert C. Green, MD, MPH
Fellow in Genetics/Professor of Neurology, Genetics, and Epidemiology
Division of Genetics, Department of Medicine
Brigham and Women’s Hospital
Harvard Medical School
Boston, MA
Nothing to disclose
Michael D. Greicius, MD, MPH
Medical Director, Stanford Memory Clinic
Stanford Hospitals & Clinics
Assistant Professor of Neurology
Stanford University School of Medicine
Stanford, CA
Patient Safety Monitoring Panel: Forest
John Olichney, MD
Associate Professor of Neurology
Center for Mind and Brain
UC Davis School of Medicine
Sacramento, CA
Nothing to disclose
Lon Schneider, MD, MS
Professor of Psychiatry, Neurology, and Gerontology
Keck School of Medicine
University of Southern California
Director, California Alzheimer's Disease Center
Do-director, Clinical Core
University of Southern California Alzheimer's Disease Research Center
Los Angeles, CA
Grant funding, contracts, and/or consulting: Lilly, Myriad, Lundbeck, Elan, Johnson and Johnson, Pfizer, Transition.
Thomas Wisniewski MD
Professor of Neurology, Pathology and Psychiatry
New York University School of Medicine
Dept. of Neurology, Psychiatry and Pathology
New York, NY
Nothing to disclose
Program Managers and Web Editor Disclosure Program Manager Gideon Bosker, MD has nothing to disclose.
Program Reviewer Denise Leary has nothing to disclose.
Educational Objectives
Upon completion of this activity, participants will be able to:
- Detail the epidemiology and burden of Alzheimer’s disease, with a focus on special considerations and challenges that apply to patients with moderate and severe AD.
- Understand the role of dysregulation of cholinergic transmission as one of the key underpinnings for deterioration of cognitive and related symptoms in AD, and the implications for therapeutic interventions based on associated disruptions in neurotransmission.
- Stage patients with moderate or severe AD; and, be more skilled at pharmacologic management of patients with advancing disease.
- Deploy agents in the current pharmacologic armamentarium for moderate and severe AD, including both those options that stimulate the cholinergic system, and that work through NMDA receptors.
- Deploy agents indicated and approved for treatment of moderate and severe AD, what dosage options are available for cholinesterase inhibitors, based on evidence derived from clinical trials demonstrate; and, better understand the relationships among dosage of ChEIs, cognitive improvement, and global function.
- Treat patients with moderate, moderately severe, and severe AD based on national guidelines and consensus-based recommendations for managing this patient population.
- Manage patients with moderate and severe AD when cholinergic stimulation is deployed as the foundation strategy for management; and better skilled at evaluating dosage options and available formulations in order to select evidence- and trial-based solutions that optimize both cognitive and global function outcomes in patients with AD.
- Manage patients in the outpatient, assisted living, and chronic care setting will become better able to apply expert-based guidelines for agents indicated for treatment of moderate or severe AD.
Hardware and Software Requirements:
To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate..
Privacy Policy
When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:
- We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
- For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
- We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
- If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
- You should check this privacy policy periodically to see whether we have made any changes.
Disclaimer
Copyright © 2011 by Pharmatecture, LLC and CMEducation Resources, LLC All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.
Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.
Copyright © CMEducation Resources, LLC and Pharmatecture, LLC
Click here to indicate that you have read this CME information statement and wish to participate in this CME activity.
